| dataOvarian {frailtypack} | R Documentation |
Advanced Ovarian Cancer dataset
Description
This dataset combines the data that were collected in four double-blind randomized clinical trials in advanced ovarian cancer. In these trials, the objective was to examine the efficacy of cyclophosphamide plus cisplatin (CP) versus cyclophosphamide plus adriamycin plus cisplatin (CAP) to treat advanced ovarian cancer. The candidate surrogate endpoint S is progression-free survival time, defined as the time (in years) from randomization to clinical progression of the disease or death. The true endpoint T is survival time, defined as the time (in years) from randomization to death of any cause
Usage
data(dataOvarian)
Format
This data frame contains the following columns:
- patientID
The identification number of a patient
- trialID
The center in which a patient was treated
- trt
The treatment indicator, coded as 0 = cyclophosphamide plus cisplatin (CP) and 1 = cyclophosphamide plus adriamycin plus cisplatin(CAP)
- timeS
The candidate surrogate (progression-free survival)
- statusS
Censoring indicator for for Progression-free survival
- timeT
The true endpoint (survival time)
- statusT
Censoring indicator for survival time
Source
Ovarian cancer Meta-Analysis Project (1991). Cyclophosphamide plus cisplatin plus adriamycin versus Cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. Classic Papers and Current Comments, 3, 237-234.